Skip to main content
SpringerLink
Log in

Not ready for prime time: aliskiren for treatment of hypertension or proteinuria in children

  • Letter to the Editors
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Schreiner MS (2003) Paediatric clinical trials: redressing the imbalance. Nat Rev Drug Discov 2:949–961

    Article  PubMed  CAS  Google Scholar 

  2. Pandolfini C, Bonati M (2005) A literature review on off-label drug use in children. Eur J Pediatr 164:552–558

    Article  PubMed  Google Scholar 

  3. Cuzzolin L, Atzei A, Fanos V (2006) Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf 5:703–718

    Article  PubMed  Google Scholar 

  4. Stanton A, Jensen C, Nussberger J, Obrien E (2003) Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42:1137–1143

    Article  PubMed  CAS  Google Scholar 

  5. Rakusan D, Kujal P, Kramer HJ, Husková Z, Vanourková Z, Vernerová Z, Mrázová I, Thumová M, Cervenka L, Vanecková I (2010) Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. Am J Physiol Renal Physiol 299:F758–F766

    Article  PubMed  CAS  Google Scholar 

  6. Kelland EE, McAuley LM, Filler G (2011) Are we ready to use aliskiren in children? Pediatr Nephrol. doi:10.1007/s00467-010-1702-z

    Google Scholar 

  7. Spiller HA (2008) Hypotension after ingestion of aliskiren. Clin Toxicol 46:916–917

    Article  Google Scholar 

Download references

Disclosure statement

Joseph Flynn is a consultant to Novartis Pharmaceuticals, Inc., the manufacturer of aliskiren. No industry funding was involved with data collection or the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Division of Nephrology, Seattle Children’s Hospital, Department of Pediatrics, University of Washington School of Medicine, 4800 Sand Point Way NE, M/S A-7931, Seattle, WA, 48105, USA

    Joseph T. Flynn

Authors
  1. Joseph T. Flynn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph T. Flynn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Flynn, J.T. Not ready for prime time: aliskiren for treatment of hypertension or proteinuria in children. Pediatr Nephrol 26, 491–492 (2011). https://doi.org/10.1007/s00467-010-1726-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-010-1726-4

Keywords

Search

Navigation